Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor commonly prescribed for the improvement of glycemic control as an adjunctive therapy to diet and exercise in patients with type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and diabetes mellitus.